21.59
-0.18 (-0.83%)
Previous Close | 21.77 |
Open | 21.71 |
Volume | 9,616,616 |
Avg. Volume (3M) | 14,343,636 |
Market Cap | 41,393,643,520 |
Price / Earnings (TTM) | 39.25 |
Price / Earnings (Forward) | 17.70 |
Price / Sales | 2.67 |
Price / Book | 3.87 |
52 Weeks Range | |
Earnings Date | 6 Feb 2025 - 10 Feb 2025 |
TTM Dividend Yield | 3.75% |
Profit Margin | 6.88% |
Operating Margin (TTM) | 19.85% |
Diluted EPS (TTM) | 0.550 |
Quarterly Revenue Growth (YOY) | -0.40% |
Quarterly Earnings Growth (YOY) | -12.60% |
Total Debt/Equity (MRQ) | 82.93% |
Current Ratio (MRQ) | 1.00 |
Operating Cash Flow (TTM) | 1.93 B |
Levered Free Cash Flow (TTM) | 1.52 B |
Return on Assets (TTM) | 6.50% |
Return on Equity (TTM) | 9.88% |
Market Trend
Short Term | Medium Term | ||
Industry | Household & Personal Products (US) | Bullish | Mixed |
Household & Personal Products (Global) | Bullish | Mixed | |
Stock | Kenvue Inc. | Bullish | Bullish |
AIStockmoo Score
Analyst Consensus | 3.0 |
Insider Activity | NA |
Price Volatility | -1.0 |
Technical Moving Averages | 2.5 |
Technical Oscillators | -0.5 |
Average | 1.00 |
Kenvue is the world’s largest pure-play consumer health company by sales, generating $15 billion in annual revenue. Formerly known as Johnson & Johnson’s consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women’s health. Its portfolio includes a wide array of some of the most well-known brands in the space, including Tylenol, Listerine, Johnson’s, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and ever-changing consumer preferences, many of Kenvue’s brands are the global leader in their respective segment thanks to their strong brand power. |
|
Sector | Consumer Defensive |
Industry | Household & Personal Products |
Investment Style | Mid Core |
% Held by Insiders | 0.02% |
% Held by Institutions | 99.77% |
52 Weeks Range | ||
Price Target Range | ||
High | 27.00 (B of A Securities, 25.06%) | Buy |
Median | 25.00 (15.79%) | |
Low | 24.00 (Deutsche Bank, 11.16%) | Hold |
Average | 25.33 (17.32%) | |
Total | 2 Buy, 1 Hold | |
Avg. Price @ Call | 22.24 |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
Deutsche Bank | 12 Dec 2024 | 24.00 (11.16%) | Hold | 22.32 |
B of A Securities | 22 Oct 2024 | 27.00 (25.06%) | Buy | 22.93 |
JP Morgan | 11 Oct 2024 | 25.00 (15.79%) | Buy | 21.46 |
No data within this time range.
Date | Type | Details |
---|---|---|
25 Nov 2024 | Announcement | Kenvue Announces Participation in the Morgan Stanley Global Consumer & Retail Conference |
07 Nov 2024 | Announcement | Kenvue Reports Third Quarter 2024 Results |
07 Nov 2024 | CNBC | FDA proposes ending use of decongestant found in many cold, allergy medicines |
31 Oct 2024 | Announcement | Neutrogena® Launches Breakthrough Collaboration with Two of World’s Most Recognizable Dermatologists |
18 Oct 2024 | Announcement | Kenvue to Announce Third Quarter 2024 Results on November 7, 2024 |
17 Oct 2024 | Announcement | Kenvue Declares Quarterly Cash Dividend |
TTM Dividend Yield | 3.75% |
1Y Average Dividend Yield | 1.86% |
Payout Ratio | 146.36% |
Expected Next Dividend Payment | Feb 2025 |
Ex Date | Announcement Date | Payment Date | Details |
---|---|---|---|
13 Nov 2024 | 17 Oct 2024 | 27 Nov 2024 | 0.205 Cash |
14 Aug 2024 | 25 Jul 2024 | 28 Aug 2024 | 0.205 Cash |
07 May 2024 | 25 Apr 2024 | 22 May 2024 | 0.2 Cash |
13 Feb 2024 | 25 Jan 2024 | 28 Feb 2024 | 0.2 Cash |
07 Nov 2023 | 26 Oct 2023 | 22 Nov 2023 | 0.2 Cash |
25 Aug 2023 | 20 Jul 2023 | 07 Sep 2023 | 0.2 Cash |
Annual Dividend Yield
Year | Annual Dividend ($) | Frequency/Year | Yield % |
---|---|---|---|
2024 | 0.810 | 4 | 3.75 |
2023 | 0.400 | 2 | 1.86 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2024 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |